Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

858

Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population

Francesco Natale1, Ettore Luisi1,2, Rosa Franzese1,2

  • 1Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy.

Journal of Cardiovascular Development and Disease
|May 24, 2024
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists, like semaglutide, show promise in managing type 2 diabetes and obesity. Emerging evidence highlights their cardiovascular protective effects, offering new therapeutic avenues.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular diseases are a leading global cause of death and disability.
  • Despite advances, cardiovascular mortality continues to rise.
  • Novel therapeutic targets and drugs are needed for cardiometabolic risk factors.

Purpose of the Study:

  • To review the cardiovascular benefits of GLP-1 receptor agonists (GLP-1RAs).
  • To focus on semaglutide, a GLP-1RA with demonstrated cardiovascular outcome efficacy.
  • To characterize patient populations benefiting from semaglutide for cardiovascular health.

Main Methods:

  • Review of recent scientific literature and clinical publications on semaglutide.
  • Analysis of data regarding GLP-1RAs' effects on cardiometabolic pathways and inflammation.
  • Evaluation of evidence supporting cardiovascular protection by GLP-1RAs.

Main Results:

  • GLP-1 receptor agonists (GLP-1RAs) are effective in glycemic control and obesity management.
  • GLP-1RAs demonstrate a protective role in cardiovascular health.
  • Semaglutide has shown efficacy in improving cardiovascular outcomes.

Conclusions:

  • GLP-1RAs, particularly semaglutide, offer significant cardiometabolic benefits.
  • The anti-inflammatory effects and widespread receptor distribution of GLP-1RAs contribute to their versatility.
  • Further characterization of patient subgroups benefiting from semaglutide for cardiovascular outcomes is warranted.

Keywords:
cardiometabolic diseasesglucagon-like peptide-1 receptor agonistssemaglutide

More Related Videos

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes08:44

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Published on: July 30, 2020

4.4K
Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.0K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
173
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167